Cullinan Therapeutics “announced first clinical data from its Phase 1 dose escalation cohort of CLN-619 in combination with checkpoint inhibitor pembrolizumab and updated results from the monotherapy dose escalation cohort in patients with advanced solid tumors. Findings from the clinical trial will be shared at the 2024 American Society of Clinical Oncology Annual Meeting as a poster presentation during the “Developmental Therapeutics-Immunotherapy” session on June 1, 2024, 9:00 AM-12:00 PM Central Time. Of 22 patients treated with CLN-619 in combination with pembrolizumab, 18 were RECIST-evaluable for response. Confirmed partial responses (PR) were observed in 3 patients treated with CLN-619 at doses greater than or equal to3mg/kg in combination with pembrolizumab. Responses were observed in patients with tumor types not typically responsive to CPI treatment.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
- Cullinan Therapeutics files to sell 14.4M shares of common stock for holders
- Cullinan Therapeutics price target lowered to $28 from $29 at H.C. Wainwright
- Cullinan Management Welcomes David Meek to Board of Directors
- Cullinan Therapeutics reports Q1 EPS (86c), consensus (99c)